Catamaran Bio Revenue and Competitors
Estimated Revenue & Valuation
- Catamaran Bio's estimated annual revenue is currently $3.7M per year.
- Catamaran Bio's estimated revenue per employee is $77,500
- Catamaran Bio's total funding is $42M.
Employee Data
- Catamaran Bio has 48 Employees.
- Catamaran Bio grew their employee count by -21% last year.
Catamaran Bio's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Technical Operations | Reveal Email/Phone |
2 | VP, Finance & Operations | Reveal Email/Phone |
3 | VP, Technical Operations and Manufacturing | Reveal Email/Phone |
4 | VP, Human Resources and Organizational Effectiveness | Reveal Email/Phone |
5 | SVP, Corporate Strategy and New Product Planning | Reveal Email/Phone |
6 | SVP, Corporate Strategy and New Product Planning | Reveal Email/Phone |
7 | Associate Director | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Chief Financial Officer | Reveal Email/Phone |
10 | Chief Medical Officer | Reveal Email/Phone |
Catamaran Bio Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Catamaran Bio?
At Catamaran, our mission is to harness the power of our proprietary TAILWIND™ Platform to develop safe and effective, off-the-shelf, allogeneic immune cell therapies for the treatment of patients with cancer and immune disorders.
keywords:N/A
$42M
Total Funding
48
Number of Employees
$3.7M
Revenue (est)
-21%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Catamaran Bio News
Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT?179, a HER2-targeted Allogeneic CAR-NK Cell Therapy. ...
BUSINESS WIRE)-- Catamaran Bio, Inc., a biotechnology company developing off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies to...
He most recently was chief medical officer of biotech startup Catamaran Bio Inc. and before that held the same position with biotech company...
Catamaran Bio has raised $42 million in a Series A co-led by Sofinnova Partners and Lightstone Ventures. Based in the Boston area, the company is a developer of cell therapies intended to treat solid tumors. Additional Investors SV Health Investors, Takeda Ventures, Astellas Venture Management
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $59.4M | 48 | -51% | $63.9M |
#2 | $9.6M | 48 | 4% | N/A |
#3 | $7.4M | 48 | 30% | N/A |
#4 | $6.9M | 48 | N/A | N/A |
#5 | $1.7M | 48 | 2% | N/A |